.webp)
Randomized German trial: Axia’s tailored exercises, education, and gamification drove greater disease activity, function, and quality-of-life gains.
Researchers in Germany conducted a randomized controlled study that showed patients with axial spondyloarthritis (axSpA) receiving the Axia smart phone app in addition to standard of care experienced better improvements in disease activity, functional ability and quality of life than patients receiving standard of care only. There were 200 adult participants enrolled in this 12 week study.
The Axia app combines disease specific tailored exercises, patient education, self management tools and gamification elements including daily routines, milestone tracking, step goals and smart watch integration. This integrated approach addresses a persistent clinical challenge like translating guideline based exercise recommendations into sustained patient engagement and long term adherence within routine care settings.
Results demonstrated clinically meaningful improvements across multiple outcome measures. Axia users reported significantly greater reductions in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores (group difference, -1.508; P < .001), Bath Ankylosing Spondylitis Functional Index (BASFI) scores (group difference, -1.139; P < .001), and Ankylosing Spondylitis Quality of Life (ASQOL) scores (group difference, -2.297; P < .001), all exceeding established thresholds for minimal clinically important differences.
In the app cohort, response rates to standard-assessment criteria were significantly higher: 51% of Axia users achieved ASAS20 response, compared with 9% in the control group, and 23% achieved ASAS40, compared with 3% in the control group (P < 0.001 for both outcomes). Improvements in pain, global assessment by patient, self-efficacy, and adherence to exercise were all greater in the Axia group than the control group.
Engagement effectiveness is further shown via adherence metrics, with Axia users utilizing a mean average of 1,145 minutes over a mean of 69 days, with 77.9% using the app for at least five of the seven days per week. 98.9% of participants opted to continue to utilize Axia following a trial period; the number of overall adverse events was lower in the app group (22% versus 37%); and no device-related adverse events were reported.
Business Honor sees integrating the Axia app as a strategic move to improve patient outcomes and company positioning.
.webp)
